Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Pancreatic cancer screening

Introduction

Overview

Overview

The U.S. Preventive Services Task Force (USPSTF) recommends against screening for pancreatic cancer in asymptomatic, average-risk adults (Grade D). There is no evidence that screening, or treatment of screen-detected disease, reduces morbidity or mortality, and the harms are at least moderate.[1]

Targeted surveillance is recommended for high-risk individuals. This group includes carriers of a pathogenic or likely pathogenic (P/LP) germline variant in a pancreatic cancer susceptibility gene and people with a qualifying family history, generally a lifetime risk above 5%. NCCN, ASGE, AGA, and the International Cancer of the Pancreas Screening (CAPS) Consortium recommend annual contrast-enhanced magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS), performed at experienced high-volume centers.[2][3][4]

The case for surveillance in enriched populations rests on stage. Pancreatic ductal adenocarcinoma (PDAC) has a lifetime risk of only about 1.3%–1.7% in the general population. It is still the third-leading cause of U.S. cancer death, with about 13% overall 5-year survival. Most cases present at regional or distant stage, where 5-year survival is 3%–16%, whereas survival for stage IA disease approaches about 80%.[5][6] About 10% of PDAC is attributable to hereditary predisposition, and current surveillance targets only this fraction of the disease burden.[7][8]

Screening

Screening

Average-risk individuals

  • Screening is not recommended (USPSTF Grade D, 2019 reaffirmation of the 2004 recommendation). In a low-prevalence population, false-positive findings drive downstream testing and surgery with no demonstrated benefit.[1]
  • The Grade D recommendation applies to asymptomatic adults with new-onset diabetes, smoking, obesity, or chronic pancreatitis. It does not apply to people with inherited cancer syndromes or familial pancreatic cancer.[1]
  • New-onset diabetes mellitus (NOD) carries a standardized incidence ratio for PDAC of only about 1.5. Prediction models are not yet validated for routine use, and there is no demonstrated survival benefit, so NOD alone does not warrant imaging-based screening. It remains an active research focus.[9][10]
  • Chronic pancreatitis raises relative risk about 7-fold, but the absolute risk is too low to justify screening.[11]
  • CA 19-9 is not a validated screening biomarker, and no accurate liquid biomarker is currently available.[9][12]

High-risk individuals

High-risk individuals fall into two groups:

  • Carriers of P/LP germline variants in PDAC susceptibility genes.
  • People with a qualifying family history, including familial pancreatic cancer (FPC) kindreds.[2][6]

NCCN criteria (category 2A) are shown below. For every row, surveillance may start earlier: at 10 years younger than the youngest affected relative.[2][3]

High-risk groups eligible for pancreatic cancer surveillance
Group Family history requirement (NCCN) Starting age (NCCN) Comments
STK11 (Peutz-Jeghers syndrome) None; screen regardless of family history 30–35 years Highest relative risk (RR ~132). AGA and ASGE start at age 35.[2][10][4]
CDKN2A (familial atypical multiple mole melanoma [FAMMM]) None; screen regardless of family history 40 years [2][9][13]
ATM, BRCA2 ≥1 first- or second-degree relative with exocrine PDAC on the same side of the family 50 years ASGE/AGA may offer surveillance without family history (see disagreements below).[2][8]
BRCA1, PALB2, TP53, MLH1, MSH2, MSH6, EPCAM (3′ deletions affecting MSH2; Lynch syndrome) ≥1 first- or second-degree relative with exocrine PDAC on the same side as the variant 50 years TP53 carriers usually have whole-body MRI surveillance, which images the pancreas, so separate pancreatic imaging is often unnecessary.[2][8]
Familial pancreatic cancer without an identified variant ≥2 first-degree relatives (FDRs); or 1 FDR plus ≥1 second-degree relative; or ≥3 affected relatives (≥1 an FDR) with exocrine PDAC 50–55 years CAPS experts were split between age 50 and 55.[2][6][3]
Hereditary pancreatitis (PRSS1 variant plus clinical phenotype) None required 20 years after pancreatitis onset or age 40, whichever is earlier ASGE/AGA use age 40. CAPS reached no consensus, and ACR advises against screening (see below).[2][14][11]
  • Not PDAC surveillance indications: familial adenomatous polyposis, Von Hippel-Lindau disease, and multiple endocrine neoplasia type 1. The pancreatic tumors relevant to VHL and MEN1 are neuroendocrine.[2][4]
  • Multisociety guidance does not recommend PDAC screening for chronic pancreatitis associated with SPINK1, CFTR, CTRC, CPA1, or CEL.[14]
  • A single FDR with PDAC and no other risk factor confers about a 2-fold risk (about 3% lifetime risk). This does not justify surveillance on its own, but it does justify germline testing.[2][15]

Germline genetic testing

  • Offer germline genetic testing, preferably with a multigene panel, to:
    • All patients with PDAC, regardless of family history.
    • Unaffected individuals with an FDR who had PDAC.
    • Unaffected individuals with a known familial P/LP variant.[2][16][17]

Screening modalities, interval, and setting

  • Preferred tests: contrast-enhanced MRI/MRCP and/or EUS, performed annually when no concerning lesion is present.[2][3][15]
  • The two modalities complement each other. EUS better visualizes small solid lesions, and MRCP better detects small cysts. Their accuracy for high-grade dysplasia and early PDAC appears similar, and the added value of MRI on top of EUS is debated.[15][9][4]
  • ASGE recommends choosing EUS, MRI, or alternating between them based on patient factors:[4]
    • EUS is preferred for very-high-risk carriers (Peutz-Jeghers syndrome, FAMMM), when it can be combined with upper endoscopy or colonoscopy, or when MRI is contraindicated.
    • MRI is preferred to avoid invasive testing or anesthesia.
  • Escalation: in an established high-risk individual, a concerning lesion or new-onset diabetes should prompt further diagnostic studies or a shorter surveillance interval.[10][18]
  • Setting: surveillance should take place at high-volume centers, ideally within a longitudinal research protocol. In-depth counseling should come first and cover cost, the frequency of benign or indeterminate findings, and the uncertain benefit.[2][3][19]
  • Stopping surveillance: consider stopping when the patient is more likely to die of non-PDAC causes, or has comorbidities that would preclude resection. There is no firm consensus on this.[20]

Guideline disagreements and areas of uncertainty

  • Moderate-risk genes without family history: NCCN and ACG require an affected FDR or second-degree relative for BRCA1, ATM, PALB2, and the Lynch genes. ASGE and AGA offer surveillance to BRCA2, BRCA1, and PALB2 carriers based on a lifetime-risk threshold above 5%, even without family history.[15][19][8]
  • Family history requirement for variant carriers: CAPS considers carriers with only one affected FDR eligible for surveillance.[3][8]
  • Starting age for FPC: CAPS experts were split between age 50 and 55.[3]
  • Hereditary pancreatitis: CAPS reached no consensus. ACR advises against imaging surveillance in chronic or hereditary pancreatitis because inflammation and calcification confound interpretation. This conflicts with NCCN and ASGE recommendations to screen PRSS1 carriers.[3][12][11]
  • Modality strategy: whether to alternate modalities, and the incremental value of combining MRI with EUS, remain unresolved.[9][3]

Common pitfalls

  • Applying average-risk logic (“do not screen”) to true high-risk carriers. The opposite error is screening average-risk patients because of NOD or a single affected FDR.[9][15]
  • Performing surveillance outside high-volume centers, which leads to overinvestigation of benign cysts.[2]
  • Treating FAP, VHL, MEN1, or CFTR-associated chronic pancreatitis as PDAC screening indications.[2][14]
  • Missing new-onset diabetes in an established high-risk individual, which should trigger escalation.[10][18]
References

References

  1. ↑ 1.0 1.1 1.2 US Preventive Services Task Force, Owens DK, Davidson KW; et al. (2019). “Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement”. JAMA. 322 (5): 438–444. doi:10.1001/jama.2019.10232. PMID 31386141.
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 1.2027. Updated August 31, 2026. https://www.nccn.org/guidelines
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Goggins M, Overbeek KA, Brand R; et al. (2020). “Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium”. Gut. 69 (1): 7–17. doi:10.1136/gutjnl-2019-319352. PMID 31672839.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 Sawhney MS, Calderwood AH, Thosani NC; et al. (2022). “ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations”. Gastrointest Endosc. 95 (5): 817–826. doi:10.1016/j.gie.2021.12.001. PMID 35183358 Check |pmid= value (help).
  5. ↑ Genkinger JM, Klein AP (2025). “Why is earlier detection, the key to reducing pancreatic cancer, so challenging despite technological advances?”. J Clin Oncol. 43 (26): 2843–2846. doi:10.1200/JCO-25-00796.
  6. ↑ 6.0 6.1 6.2 Ahmed TM, Kawamoto S, Lopez-Ramirez F; et al. (2024). “Early detection of pancreatic cancer in the era of precision medicine”. Abdom Radiol (NY). 49 (10): 3559–3573. doi:10.1007/s00261-024-04358-w.
  7. ↑ Roth S, Apte M, Balachandran VP; et al. (2026). “Pancreatic cancer”. Nat Rev Dis Primers. 12 (1): 23. doi:10.1038/s41572-026-00699-6.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Karloski E, Dudley B, Diergaarde B; et al. (2024). “The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: results of a multi-center collaboration”. Cancer. 130 (19): 3297–3304. doi:10.1002/cncr.35383.
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 Stoop TF, Javed AA, Oba A; et al. (2025). “Pancreatic cancer”. Lancet. 405 (10485): 1182–1202. doi:10.1016/S0140-6736(25)00261-2.
  10. ↑ 10.0 10.1 10.2 10.3 Aslanian HR, Lee JH, Canto MI (2020). “AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review”. Gastroenterology. 159 (1): 358–362. doi:10.1053/j.gastro.2020.03.088.
  11. ↑ 11.0 11.1 11.2 Thierens N, Verdonk RC, Löhr JM; et al. (2024). “Chronic pancreatitis”. Lancet. 404 (10471): 2605–2618. doi:10.1016/S0140-6736(24)02187-1.
  12. ↑ 12.0 12.1 Expert Panel on Gastrointestinal Imaging, Fung A, Zaheer A; et al. (2025). “ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update”. J Am Coll Radiol. 22 (11S): S610–S624. doi:10.1016/j.jacr.2025.08.037.
  13. ↑ Jayakrishnan T, Ng K (2025). “Early-onset gastrointestinal cancers: a review”. JAMA. 334 (15): 1373–1385. doi:10.1001/jama.2025.10218.
  14. ↑ 14.0 14.1 14.2 Calderwood AH, Sawhney MS, Thosani NC; et al. (2022). “American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence”. Gastrointest Endosc. 95 (5): 827–854.e3. doi:10.1016/j.gie.2021.12.002.
  15. ↑ 15.0 15.1 15.2 15.3 15.4 Stoffel EM, Brand RE, Goggins M (2023). “Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention”. Gastroenterology. 164 (5): 752–765. doi:10.1053/j.gastro.2023.02.012.
  16. ↑ Park W, Chawla A, O’Reilly EM (2021). “Pancreatic cancer: a review”. JAMA. 326 (9): 851–862. doi:10.1001/jama.2021.13027.
  17. ↑ Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O’Reilly EM (2020). “An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review”. JAMA Oncol. 6 (5): 764–771. doi:10.1001/jamaoncol.2019.5963.
  18. ↑ 18.0 18.1 Wood LD, Canto MI, Jaffee EM, Simeone DM (2022). “Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment”. Gastroenterology. 163 (2): 386–402.e1. doi:10.1053/j.gastro.2022.03.056.
  19. ↑ 19.0 19.1 Monahan K, Hampel H, Stoffel E, Kupfer SS (2025). “In our scope of practice: genetic risk assessment and testing for gastrointestinal cancers and polyposis in gastroenterology”. Gastroenterology. 169 (6): 1147–1165. doi:10.1053/j.gastro.2025.06.001.
  20. ↑ Shen MJ, Jamali A, Katona BW (2025). “Challenges of early detection of pancreatic cancer”. J Clin Invest. 135 (20): e191942. doi:10.1172/JCI191942.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Aravind Reddy Kothagadi M.B.B.S[3]